Related content

A Placebo controlled double blind study in obsessive compulsive disorder with fluvoxamine

By Kudo Y.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 371-372

Elsevier

Access to resources Recommend Favorite

Single photon emission computed tomography (HMPAO-SPECT) in obsessive compulsive disorder, after symptom provocation with m-chlorophenylpiperazine

By K. L.H.P.   de Leeuw A.S.   de Bruin W.I.   den Boer J.A.   Westenberg H.G.M.   Buijs J.   Anema P.   van Rijk P.P.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 369-369

Elsevier

Access to resources Recommend Favorite

Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder

By Dell’Osso Bernardo   Allen Andrea   Hollander Eric  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 15, 2005-12 ,pp. : 2727-2740

Informa Healthcare

Access to resources Recommend Favorite

Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

By Askari Neda  

CNS Drugs, Vol. 26, Iss. 10, 2012-10 ,pp. : 883-892

Adis International

Access to resources Recommend Favorite

Higher serotonin transporter availability in early‐onset obsessive–compulsive disorder patients undergoing escitalopram treatment: A [¹¹C]DASB PET study

By  

Human Psychopharmacology: Clinical And Experimental (Electronic), Vol. 33, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite